Katherine Li

Ms. Katherine Li

University of Manitoba, Winnipeg, Manitoba, Canada
+1
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2020 in Viruses
Verified
Journal Article
Open access
PDF file
RCRupert Capina
Rupert Capina
KLKatherine Li
Katherine Li
LKLevon Kearney
Levon Kearney
AVAnne-Mieke Vandamme
Anne-Mieke Vandamme
PHP. Richard Harrigan
P. Richard Harrigan
KLKristel Van Laethem
Kristel Van Laethem
Next-generation sequencing (NGS) in HIV drug resistance (HIVDR) testing has the potential to improve both clinical and public health settings, however it challenges the normal operations of quality management systems to be more flexible due to its complexity, massive data generation, and rapidly evolving protocols. While guidelines for quality management in NGS data have previously been outlined, little guidance has been implemented for NGS-based HIVDR testing. This document summarizes quality control procedures for NGS-based HIVDR testing laboratories using a laboratory information systems (LIS) framework. Here, we focus in particular on the quality control measures applied on the final sequencing product aligned with the recommendations from the World Health Organization HIV Drug Resistance Laboratory Network.

26 May 2022 in Viruses
Verified
Journal Article
Open access
PDF file
KLKatherine Li
Katherine Li
CLConnor Lowey
Connor Lowey
PSPaul Sandstrom
Paul Sandstrom
HJHezhao Ji
Hezhao Ji
In silico methods for immune epitope prediction have become essential for vaccine and therapeutic design, but manual intra-species comparison of putative epitopes remains challenging and subject to human error. Created initially for analyzing SARS-CoV-2 variants of concern, comparative analysis of variant epitope sequences (CAVES) is a novel tool designed to carry out rapid comparative analyses of epitopes amongst closely related pathogens, substantially reducing the required time and user workload. CAVES applies a two-level analysis approach. The Level-one (L1) analysis compares two epitope prediction files, and the Level-two (L2) analysis incorporates search results from the IEDB database of experimentally confirmed epitopes. Both L1 and L2 analyses sort epitopes into categories of exact matches, partial matches, or novel epitopes based on the degree to which they match with peptides from the compared file. Furthermore, CAVES uses positional sequence data to improve its accuracy and speed, taking only a fraction of the time required by manual analyses and minimizing human error. CAVES is widely applicable for evolutionary analyses and antigenic comparisons of any closely related pathogen species. CAVES is open-source software that runs through a graphical user interface on Windows operating systems, making it widely accessible regardless of coding expertise. The CAVES source code and test dataset presented here are publicly available on the CAVES GitHub page.

20 July 2026 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
KLKatherine Li
Katherine Li
PSPaul Sandstrom
Paul Sandstrom
HJHezhao Ji
Hezhao Ji
Background: With increased transmission but reduced disease severity, the Omicron SARS‐CoV‐2 variants have contributed to the multifaceted transition of COVID‐19 from a global pandemic to an endemic disease. Nonetheless, the persistence of hypermutable viral variants and their ability to infect both vaccinated and previously infected individuals raise concerns about continued viral evolution and immune evasion. Methods: This study employs comprehensive in silico analyses to compare the five former variants of concern (VOCs) to elucidate their T cell antigenic variations in relation to human leukocyte antigen (HLA) recognition and binding. Results: Our major histocompatibility complex (MHC) class I and II epitope predictions suggest that the Omicron BA.1 variant harbors more putative epitopes than other VOCs (2.0–11.0 times more). Moreover, the distribution of predicted MHC‐II epitopes across HLA alleles differs substantially, with Omicron displaying significant differences from at least three VOCs in all analyses. Investigation of HLA‐epitope binding affinities indicates that Omicron epitopes often exhibit enhanced HLA binding compared with the Wuhan Reference (57.8%, 81.8%, and 60.0% of MHC‐I, MHC‐II regular, and MHC‐II promiscuous pairs, respectively), which could influence immune responses. Conclusions: These findings reveal marked differences in the putative epitope profiles of Omicron BA.1 and the Wuhan Reference, as well as other pre‐Omicron VOCs, highlighting its altered HLA recognition status. Given the continued transmission and emergence of new SARS‐CoV‐2 lineages, this study highlights the importance of ongoing research to understand the evolutionary dynamics of high‐risk SARS‐CoV‐2 variants, their host immune system interactions, and the downstream implications in vaccine and therapeutic development.